Pembrolizumab Administration Frequency, Dose Exposure, and Toxicity: Is Switching Safe?

J Thorac Oncol. 2022 Oct;17(10):1155-1157. doi: 10.1016/j.jtho.2022.07.008.

Authors

Giannis Mountzios¹, Charu Aggarwal²

Affiliations

¹ Fourth Oncology Department and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece. Electronic address: gmountzios@gmail.com.
² Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Abramson Cancer Center, Philadelphia, Pennsylvania.

PMID: 36192075
DOI: 10.1016/j.jtho.2022.07.008

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Dose-Response Relationship, Drug
Humans
Lung Neoplasms* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
pembrolizumab